Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hangzhou Biotest Biotech Co.,Ltd. (688767.SS)
Hangzhou, CN
Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research, development, manufacturing, sales, and servicing of in vitro diagnostic (IVD) solutions. Operating both domestically within China and across international markets, the company provides a comprehensive range of medical testing products. Their offerings span crucial health areas including reproductive health, cancer detection, cardiovascular conditions, inflammatory markers, biochemical analysis, and various infectious diseases. This extensive portfolio also encompasses rapid diagnostic tests for COVID-19 (covering both antibody and antigen detection), as well as screening kits for drug use (utilizing urine, saliva, and hair samples) and assessing vitamin D levels. Beyond diagnostic kits and reagents, Hangzhou Biotest Biotech also supplies essential accompanying equipment, such as immunochromatography readers and fluorescence immunoassay quantitative analyzers. The company, established in 2008, is based in Hangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.67% | -4.07% | +9.37% | +3.78% | -2.73% | +1.01% | +19.77% | +69.30% | -30.73% | -30.73% | -30.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-19.9% Q1'26: +1.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-72.2% Q1'26: -222.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+4.5% Q1'26: -44.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+2.5% ★ Q1'26: -5.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.2% ★ Q1'26: -1.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.8% ★ Q1'26: -4.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.01× ★ Q1'26: -0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
559.40M
est: 2.76B (-79.7%)
|
448.37M
est: 496.00M (-9.6%)
|
693.00M
693.00M – 693.00M
+39.7% YoY
|
887.00M
887.00M – 887.00M
+28.0% YoY
|
| EBITDA |
218.04M
est: 999.69M (-78.2%)
|
35.47M
est: 179.72M (-80.3%)
|
251.10M
251.10M – 251.10M
+39.7% YoY
|
321.39M
321.39M – 321.39M
+28.0% YoY
|
| EBIT |
196.77M
est: 909.78M (-78.4%)
|
11.20M
est: 163.56M (-93.2%)
|
228.52M
228.52M – 228.52M
+39.7% YoY
|
292.49M
292.49M – 292.49M
+28.0% YoY
|
| Net Income |
169.52M
est: 892.04M (-81.0%)
|
46.80M
est: 58.49M (-20.0%)
|
155.01M
155.01M – 155.01M
+165.0% YoY
|
210.58M
210.58M – 210.58M
+35.8% YoY
|
| SGA |
85.90M
est: 285.00M (-69.9%)
|
44.92M
est: 51.24M (-12.3%)
|
71.59M
71.59M – 71.59M
+39.7% YoY
|
91.62M
91.62M – 91.62M
+28.0% YoY
|
| EPS |
1.15
est: 6.10 (-81.1%)
|
0.32
est: 0.40 (-20.0%)
|
1.06
1.06 – 1.06
+165.0% YoY
|
1.44
1.44 – 1.44
+35.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao Liu | Deputy General Manager | — | male |
| Chun Sheng Ye | Deputy General Manager | — | male |
| Hongmei Gao | Deputy GM & Director | — | female |
| Miao Miao Yu | Accounting Supervisor & Financial Director | — | female |
| Qi Jun Fei | Deputy General Manager & Secretary of the Board of Directors | — | male |
| Shujiang Wu | GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688767.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
